3101 Western Avenue
146 articles with CTI BioPharma
CTI BioPharma Corp. announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.
The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019
CTI BioPharma Corp. announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central.
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
CTI BioPharma Corp. announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel.
CTI BioPharma Corp. announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd.
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
CTI BioPharma Corp. announced that the Company will withdraw its European Marketing Authorization Application for pacritinib as a treatment for myelofibrosis.
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia
Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development
CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter and nine months ended September 30, 2018.
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November 1, 2018,
Trial to continue to full enrollment of all three treatment arms
Management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel.
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time
CTI BioPharma Corp. announced that management plans to report its second quarter 2018 financial results on Thursday, August 2, 2018
Regulatory path to include Phase 3 trial expected to begin in 2019
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab
Shares of CTI BioPharma Corp. are down more than 15 percent in premarket trading this morning after the company announced its combination treatment for B-cell non-Hodgkin lymphoma failed to meet endpoints in a late-stage trial.
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
The IDMC did not identify any drug- or dose-related safety concerns and specifically did not identify any concerns about cardiac or bleeding events.
CTI BioPharma Corp. announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York